Evox Therapeutics Ltd. has announced the appointment of Dr. Per Lundin, Co-Founder and Chief Business Officer as Chief Executive Officer (CEO) and will be appointed to its Board of Directors.

Following more than six years with the company, Dr. Antonin “Tony” de Fougerolles has decided to step down as CEO and Director of Evox. Tony will continue to support the Company as a strategic adviser.

Per has more than 15 years of experience founding, leading, and advising biotech companies developing advanced therapies, including co-founding Evox in 2016. Prior to Evox, he founded and led IsletOne Therapeutics, a cell therapy company developing allogeneic cell therapies for autoimmune and inflammatory diseases, and prior to that worked in business development and as an IP attorney in a leading European law firm. Per serves as a non-executive director of publicly listed gene therapy company Combigene and research committee member and board director of JDRF International and JDRF UK, respectively. He is a qualified European Patent Attorney with extensive leadership, business development and operational experience; he earned his PhD from the Karolinska Institute, his Master of Science in Biotechnology Engineering from the Royal Institute of Technology, and his Master of Business Administration from Stockholm University School of Business.

Per takes on the role of CEO having founded the Company in 2016 and worked closely with Tony over the last six and a half years to significantly progress the business. Evox is backed by leading venture capital investors and has since inception developed a proprietary exosome therapeutics platform technology, entered into several collaborations with renowned institutions and pharma companies, developed a dominant IP estate and advanced the Company’s proprietary pipeline toward the clinic.

“On behalf of the Board and the whole Evox team, I would like to thank Tony for his leadership and commitment to driving the Company and its innovative technology forward, and wish him all the best in the next phase of his career,” said Paul Carter, Non-Executive Chairman of Evox Therapeutics.

“Per’s strategic insight and wide-ranging experience will be invaluable as he leads Evox through its next phase of growth. Furthermore, as Co-Founder of the business, he has a deep understanding of Evox and its exosome platform,” Carter commented.

“Over the past six and a half years as CEO, I am extremely proud of the progress we have made to uncover the enormous potential of exosome therapeutics,” said Dr. Antonin de Fougerolles, outgoing CEO.

“The Company has a very promising future ahead and I look forward to continuing to support Evox’s journey in an advisory role,” he added.

Per Lundin, PhD, Chief Executive Officer and Co-Founder of Evox Therapeutics, added, “I have enjoyed working closely with Tony over the years and I look forward to leading the Company as we advance our cutting-edge technology, DeliverEX, to accelerate the development of exosome-enabled genetic medicines.”